Toxicity of dose-adjusted BEACOP regimen in the treatment of lymphoma

Abstract

Objective To analyze the toxicity of dose adjusted-BEACOP(DA-BEACOP, classic CHOP regimen plus etoposide and(or)bleomycin with or without rituximab)regimen for poor-prognosis lymphoma. Methods 89 patients with poor-prognosis lymphoma who had been treated in-patient at Peking University Third Hospital during August 2002 and February 2012 were retrospectively studied. All patients received at least 1 cycle of DA-BEACOP regimen. Results 3-4 grade adverse events were observed in 74(83.1 %)patients, most of which was myelosuppression(73 cases, 82.0 %). There was not death related with the treatment. Compared to male patients, female patients suffered higher rates of grade 3-4 of toxicity(94.2 %, 33/35 vs 75.9 %, 41/54)(P= 0.024). The rate of grade 3-4 of hematological toxicity in patients who were pretreated with≥3 cycles of chemotherapy than that in patients receiving≤2 cycles of chemotherapy(95.9 %, 47/49 vs 75.0 %, 30/40)(P= 0.004), while the rate of 3-4 hematological toxicity in pret-radiotherapy posed patients was higher than that in their counterparts who did not receive radiotherapy(95.9 %, 47/49 vs 75.0 %, 30/40)(P= 0.022). Conclusion The DA-BEACOP regimen showed manageable toxicity in patients with poor-prognosis lymphoma. Key words: Lymphoma; Antineoplastic combined chemotherapy protocols; Toxicity